Type 2 Diabetes (incretins)

Useful effects of GLP-1 receptor:

Background to the Blonde et al study in 'Diabetes' in 2006 on effects of Byetta (exenatide, Eli-Lilly), a GLP-1 mimetic:

Findings of the Blonde et al study in 'Diabetes' in 2006 on effects of Byetta (exenatide, Eli-Lilly), a GLP-1 mimetic:

Current issues with GLP-1 therapies?:

Current DPP-IV inhibitors:

]
What do incretins do:

1: Site of action of TZDs:

2: Mode of action:

1: Site of action of incretins:

2: Mode of action:

3 problems found with traditional therapies (not incretins):

About Glucagon-like Peptide 1 Receptor antagonists (GLP-1s):

Definition of Diabetes

Causes of Type 2 Diabetes Mellitus (T2DM):

% of DM cases that are type 2?

Most NB clinical features of T2DM?

Pathogenesis of Diabetic retinopathy:

Current therapies for diabetic retinopathy:

Novel treatments for diabetic retinopathy:

Facts on diabetic nephropathy:

Obesity and T2DM:

Goals of T2DM therapeutics:

HbA1C:

A 1% decrease in HbA1C levels means a decrease of:

Role of pancreas in regulation of blood glucose concentration:

Role of liver in regulation of blood glucose concentration:

Role of GIT in regulation of blood glucose concentration:

Role of peripheral stores (muscle and fat) in regulation of blood glucose concentration:

1: Site of action of sulfonylureas:

2: Mode of action:

1: Site of action of Biguanides (eg Metformin) :

2: Mode of action: